Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Gilead Sciences : GILD) Presents Phase 3 Clinical Data in HIV-1 at IDWeek 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 08:18am CEST

Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone. In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks. The data are being presented at IDWeek 2017 in San Diego (Session 228).

These data demonstrate the potential of BIC/FTC/TAF to match the efficacy of a boosted protease inhibitor regimen while also offering a high barrier to resistance and fewer interactions with other drugs, said Eric Daar, MD, Chief of the Division of HIV Medicine at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of Study 1878. The findings, along with data from three other Phase 3 studies in both treatment-experienced and treatment-nave patients, suggest that the investigational regimen of BIC/FTC/TAF may be appropriate for a broad range of people living with HIV.

In Study 1878, a total of 577 virologically suppressed adults with HIV taking regimens of boosted atazanavir (ATV) or darunavir (DRV) + abacavir/lamivudine (ABC/3TC) or FTC/tenofovir disoproxil fumarate (TDF) were randomized 1:1 to continue their bPI regimen or to switch to open-label coformulated BIC/FTC/TAF once daily. At the primary endpoint of Week 48, switching to BIC/FTC/TAF was non-inferior to continuing on a bPI regimen with 1.7 percent of patients in each group having HIV-1 RNA =50 c/mL (difference: 0.0 percent, 95 percent CI: -2.5 percent to 2.5 percent, p=1.00); the proportion of patients with HIV-1 RNA

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09/20GILEAD SCIENCES' : Trademark Application for "WILKARTI" Filed
AQ
09/20GILEAD SCIENCES : Trademark Application for "CAARTUVY" Filed by Gilead Sciences
AQ
09/20GILEAD SCIENCES' : Trademark Application for "TUCAARTI" Filed
AQ
09/20GILEAD SCIENCES : Researchers Submit Patent Application, "Inhibitors Of Bruton'S..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "WILKARTA" Has Been Filed by ..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "SIZAXTA" Has Been Filed by G..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "YUZIKART" Has Been Filed by ..
AQ
09/20GILEAD SCIENCES' : Trademark Application for "OUIKARTA" Filed
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "CYZAXTA" Has Been Filed by G..
AQ
09/20GILEAD SCIENCES : An Application for the Trademark "TUCARTY" Has Been Filed by G..
AQ
More news
News from SeekingAlpha
09/21Feds looking into free services from drug makers - WSJ 
09/21What's Next For Gilead? 
09/21Breaking Down The NASH Cirrhosis Market - Gilead Poised For Success, But Is I.. 
09/19My Quarterly Global Portfolio Update 
09/18AbbVie used kickbacks to boost Humira sales - CA insurance commissioner 
Financials ($)
Sales 2018 21 377 M
EBIT 2018 11 220 M
Net income 2018 6 650 M
Debt 2018 12 363 M
Yield 2018 3,01%
P/E ratio 2018 14,98
P/E ratio 2019 13,78
EV / Sales 2018 5,16x
EV / Sales 2019 5,12x
Capitalization 97 887 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 88,0 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.46%46 021
REGENERON PHARMACEUTICALS3.00%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170
SAREPTA THERAPEUTICS INC165.26%9 806